Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.

Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Abstract Text:

Ana C Zamora,Paul J Wolters,Harold R Collard,M Kari Connolly,Brett M Elicker,W Richard Webb,Talmadge E King,Jeffrey A Golden,

Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease (ILD) being the most common manifestation. Currently, there is no definitive therapy for this condition. The objective of the study is to investigate the use of mycophenolate mofetil (MMF) to treat scleroderma interstitial ILD. We report a retrospective chart review of 17 patients with scleroderma ILD treated with MMF (2g/day) for at least 12 months. Demographics, bronchoalveolar lavage (BAL) findings, pulmonary physiology and high-resolution computed tomography were recorded at baseline and after 12 and 24 months of therapy. Baseline BAL (n=12) showed alveolitis (median of 18% neutrophils). Ninety-four percent of subjects had either improved or stable lung function after 12 months of treatment: four improved, 12 were stable and only one worsened. All patients had radiographic abnormalities consistent with ILD. After 12 months of therapy, radiological findings (n=15) were stable in 11 patients, worse in three, and improved in one. There were no side effects attributable to MMF therapy recorded. Treatment of patients with scleroderma ILD for up to 24 months with MMF was generally associated with stable pulmonary function. These data argue for a prospective trial using MMF to treat scleroderma ILD.

Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Publishing Authors By Initials

AC Zamora,PJ Wolters,HR Collard,MK Connolly,BM Elicker,WR Webb,TE King,JA Golden,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Respiratory medicine

VOLUME: 102

Page Numbers: 150-5

Journal Abbreviation:

ISSN: 0954-6111

DAY: 5

MONTH: 09

YEAR: 2007

Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8908438

Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.

AFFILIATION: Hospital Universitario "Dr. Jose Eleuterio González" Monterrey, NL, Mexico.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Respir Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease Related Publications

• A survey of the accuracy of certain chemical determinations.
• Are opportunities for vitamin A supplementation being utilised at primary health-care clinics in the Western Cape Province of South Africa?
• Ascites in pregnancy.
• Atmospheric plasma inactivation of foodborne pathogens on fresh produce surfaces.
• Basic life support on small boats at sea.
• Bill Golden.
• Biological and demographic causes of high HIV and sexually transmitted disease prevalence in men who have sex with men.
• Collective excitations in electron-hole bilayers.
• Depression and osteoporosis: epidemiology and potential mediating pathways.
• Detection of rhythmic bioluminescence from luciferase reporters in cyanobacteria.
• Eating disorders in adolescence: what is the role of hormone replacement therapy?
• Interest in a methamphetamine intervention among men who have sex with men.
• Loneliness in older chinese adults: a risk factor for elder mistreatment.
• Long-term patterns and feeding sites of southern green stink bug (Hemiptera: Pentatomidae) in Hawaii macadamia orchards, and sampling for management decisions.
• Negative rapid HIV antibody testing during early HIV infection.
• Potential impact of human papillomavirus vaccines on public STD clinic workloads and on opportunities to diagnose and treat other sexually transmitted diseases.
• Protein extraction, fractionation, and purification from cyanobacteria.
• Quinone sensing by the circadian input kinase of the cyanobacterial circadian clock.
• Screening for acute HIV infection: lessons learned.
• Sigma factor genes sigC, sigE, and sigG are upregulated in heterocysts of the Cyanobacterium Anabaena sp. strain PCC 7120.
• Some of the newer concepts of cancer.
• Specialized techniques for site-directed mutagenesis in cyanobacteria.
• Stage-specific effects of bone morphogenetic proteins on the oligodendrocyte lineage.
• Studies on alcohol soluble fungistatic and fungicidal compounds; treatment of dermatophytosis pedis with 8-hydroxyquinoline.
• Tackling obesity from many angles.
• The Anabaena sp. strain PCC 7120 asr1734 gene encodes a negative regulator of heterocyst development.
• The reaction Cl+NO2-->ClONO and ClNO2.
• Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.
• What is anaphylaxis?
• Winding up the cyanobacterial circadian clock.